Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
3D models of human ERα and ERβ complexed with coumestrol.
Pilates based core stability training in ambulant individuals with multiple sclerosis: Protocol for a multi-centre randomised controlled trial.
Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
Physiopathology of symptoms and signs in multiple sclerosis.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Memory rehabilitation for people with multiple sclerosis.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Managing fatigue in patients with multiple sclerosis.
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.

Pages